Preventative and Personalized Approach to the Treatment of Malignant Melanoma: A Case Report.
Barre latérale de l'article
Publié-e :
mai 11, 2016
Mots-clés :
melanoma, chemotherapy, immunotherapy, management, multidisciplinary
Contenu principal de l'article
Résumé
This case report is focused on malignant melanoma, a common potentially lethal skin cancer, and its unique management. In our patient’s case, the primary cutaneous melanoma occurred 28 years prior to presenting with axillary lymphadenopathy, which was later determined to be a metastatic focus of melanoma; subsequent nodules were found in his spleen. After completion of his treatment and routine screening, additional nodules were discovered in his chest. Primary and secondary prevention were important in the management of this patient, as well as personalization of his treatment.
Cette étude de cas porte sur le mélanome malin, un cancer de la peau potentiellement mortel avec une gestion unique. Dans le cas de notre patient, le mélanome s’est présenté 28 ans avant la présentation d’une lymphadénopathie axillaire, ce qui a été démontré par la suite comme une zone étant métastatique du mélanome. Des nodules ont été découverts dans sa rate. Suite à la fin des traitements et des suivis de routine, des nodules additionnels ont été découverts dans sa poitrine. Des préventions primaires et secondaires sont importantes pour la gestion de ce patient ainsi qu’un traitement personnalisé.
Renseignements sur l'article
Rubrique
Case Report & Elective report
- Les auteurs qui publient dans le JMUO gardent les droits d’auteur de leurs articles, incluant tous les brouillons et la copie finale publiée dans le journal
- Bien que le JMUO n’a pas les droits d’auteur des articles soumis, en acceptant de publier dans le JMUO, les auteurs donnent le droit au journal d’être les premiers à publier et à distribuer leurs articles.
- Par la suite, les auteurs peuvent soumettre leurs documents à d’autres publications, incluant des revues ou des livres, avec un remerciement de leur première publication dans le JMUO
- Des copies du JMUO seront distribuées à la fois sous format papier et en ligne, et tous les matériaux seront accessibles au public en ligne. Le journal n’a pas de responsabilité légale par rapport à la distribution publique du contenu.
- Prière de vous assurer que tous les auteurs, les coauteurs et les investigateurs
- Le contenu est rendu disponible sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
Références
1. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6):djv048.
2. Melanoma Statistics [Internet]. Canadian Cancer Statistics 2015. 2015 [cited 2016 Mar 13]. Available from: http://www.cancer.ca/en/cancer-informa¬tion/cancer-type/skin-melanoma/statistics/?region=on.
3. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–3634.
4. Balch C, Gershenwald J, Soong S, et al. Final Version of 2009 AJCC Melanoma Staging and Classification [Internet]. American Society of Clinical Oncology. 2009. Available from: http://jco.ascopubs.org/content/27/36/6199.full.
5. Shoo BA, Kashani-Sabet M. Melanoma arising in African-, Asian-, Latino- and Native-American populations. Semin Cutan Med Surg. 2009;28(2):96–102.
6. Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guide¬lines for the management of cutaneous melanoma 2010. Br J Dermatol. 2010;163(2):238–256.
7. Gachon J, Beaulieu P, Sei JF, et al. First prospective study of the recogni¬tion process of melanoma in dermatological practice. Arch Dermatol. 2005;141(4):434–438.
8. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010;25(6):601–613.
9. Lange JR, Palis BE, Chang DC, Soong S-J, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol. 2007;25(11):1363–1368.
10. Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk fac¬tor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol. 2005;23(21):4735–4741.
11. Jones EL, Jones TS, Pearlman NW, et al. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 2013;148(5):456–461.
12. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer. 1997;79(12):2361–2370.
13. Newton-Bishop JA, Chang Y-M, Elliott F, et al. Relationship between sun ex¬posure and melanoma risk for tumours in different body sites in a large case-control study in a temperate climate. Eur J Cancer. 2011;47(5):732– 741.
14. Paul A, Cramer H, Lauche R, Altner N, Langhorst J, Dobos GJ. An oncology mind-body medicine day care clinic: concept and case presentation. Integr Cancer Ther. 2013;12(6):503–507.
15. Henderson MA, Burmeister B, Thompson JF, et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymph¬adenectomy: Results of an intergroup randomized trial. J Clin Oncol. 2009;27(18s).
16. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multi¬centre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–164.
17. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remis¬sion, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030.
18. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
19. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006– 2017.
20. Chapman PB, Hauschild A, Robert C, et al. Improved survival with ve¬murafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
21. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–114.
22. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF ki¬nases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):455–467.
23. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39.
24. Vennepureddy A, Thumallapally N, Motilal Nehru V, Atallah J-P, Terjanian T. Novel drugs and combination therapies for the treatment of metastatic melanoma. J Clin Med Res. 2016;8(2):63–75.
2. Melanoma Statistics [Internet]. Canadian Cancer Statistics 2015. 2015 [cited 2016 Mar 13]. Available from: http://www.cancer.ca/en/cancer-informa¬tion/cancer-type/skin-melanoma/statistics/?region=on.
3. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–3634.
4. Balch C, Gershenwald J, Soong S, et al. Final Version of 2009 AJCC Melanoma Staging and Classification [Internet]. American Society of Clinical Oncology. 2009. Available from: http://jco.ascopubs.org/content/27/36/6199.full.
5. Shoo BA, Kashani-Sabet M. Melanoma arising in African-, Asian-, Latino- and Native-American populations. Semin Cutan Med Surg. 2009;28(2):96–102.
6. Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guide¬lines for the management of cutaneous melanoma 2010. Br J Dermatol. 2010;163(2):238–256.
7. Gachon J, Beaulieu P, Sei JF, et al. First prospective study of the recogni¬tion process of melanoma in dermatological practice. Arch Dermatol. 2005;141(4):434–438.
8. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010;25(6):601–613.
9. Lange JR, Palis BE, Chang DC, Soong S-J, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol. 2007;25(11):1363–1368.
10. Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk fac¬tor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol. 2005;23(21):4735–4741.
11. Jones EL, Jones TS, Pearlman NW, et al. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 2013;148(5):456–461.
12. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer. 1997;79(12):2361–2370.
13. Newton-Bishop JA, Chang Y-M, Elliott F, et al. Relationship between sun ex¬posure and melanoma risk for tumours in different body sites in a large case-control study in a temperate climate. Eur J Cancer. 2011;47(5):732– 741.
14. Paul A, Cramer H, Lauche R, Altner N, Langhorst J, Dobos GJ. An oncology mind-body medicine day care clinic: concept and case presentation. Integr Cancer Ther. 2013;12(6):503–507.
15. Henderson MA, Burmeister B, Thompson JF, et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymph¬adenectomy: Results of an intergroup randomized trial. J Clin Oncol. 2009;27(18s).
16. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multi¬centre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–164.
17. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remis¬sion, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030.
18. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
19. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006– 2017.
20. Chapman PB, Hauschild A, Robert C, et al. Improved survival with ve¬murafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
21. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–114.
22. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF ki¬nases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):455–467.
23. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39.
24. Vennepureddy A, Thumallapally N, Motilal Nehru V, Atallah J-P, Terjanian T. Novel drugs and combination therapies for the treatment of metastatic melanoma. J Clin Med Res. 2016;8(2):63–75.